Design and optimization of selective azaindole amide M1 positive allosteric modulators.

导出原文传递

翻译打印收藏纠错

作者： Jennifer E,Davoren ^[1] ; Steven V,O'Neil ^[2] ; Dennis P,Anderson ^[2] ; Michael A,Brodney ^[3] ; Lois,Chenard ^[2] ; Keith,Dlugolenski ^[4] ; Jeremy R,Edgerton ^[4] ; Michael,Green ^[3] ; Michelle,Garnsey ^[2] ; Sarah,Grimwood ^[4] ; Anthony R,Harris ^[2] ; Gregory W,Kauffman ^[2] ; Erik,LaChapelle ^[2] ; John T,Lazzaro ^[5] ; Che-Wah,Lee ^[2] ; Susan M,Lotarski ^[4] ; Deane M,Nason ^[2] ; R Scott,Obach ^[6] ; Veronica,Reinhart ^[4] ; Romelia,Salomon-Ferrer ^[3] ; Stefanus J,Steyn ^[7] ; Damien,Webb ^[3] ; Jiangli,Yan ^[2] ; Lei,Zhang ^[3]

作者单位： Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Cambridge, MA 02139, United States. Electronic address: jennifer.e.davoren@pfizer.com. ^[1] Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Groton, CT 06340, United States. ^[2] Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Cambridge, MA 02139, United States. ^[3] Neuroscience and Pain Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA 02139, United States. ^[4] Primary Pharmacology Group, Pfizer Worldwide Research and Development, Groton, CT 06340, United States. ^[5] Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, CT 06340, United States. ^[6] Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Cambridge, MA 02139, United States. ^[7]

关键词 Azaindole amide Intra-molecular hydrogen bond (IMHB)M(1) positive allosteric modulator (PAM)M(1) selective activator